GlaxoSmithKline

GlaxoSmithKline and Johnson & Johnson are forming a $200 million fund with Index Ventures to invest in early-stage biotechnology companies, a move that may entice venture capitalists back to the industry. 
Glaxo and New Brunswick, New Jersey-based J&J will each put in $50 million, while Index Ventures will contribute $100 million and make investment decisions.
Moncef Slaoui, head of research and development at London-based Glaxo, and Paul Stoffels, J&J’s chairman of pharmaceuticals, will sit on the fund’s advisory board.
Early-stage companies have been struggling for financing as venture-capital firms turn instead to more mature businesses or less risky industries. unsecured loans
The new fund will stick to Index Ventures’ strategy of investing in early-stage, single-asset companies in Europe, the U.S. and Israel, a model the firm said has generated typical venture-capital returns in half the time.
“By investing in this fund, they are really super-powering or turbo-charging the asset-centric investment model,” said Francesco De Rubertis, the Index Ventures partner who  bad credit loans is leading the fund, in an interview in London. “They are validating it as a potential new model for early-stage R&D funding.”